A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
Clinical trial NCT01946568 · COMPLETED
Trial details
- NCT number
- NCT01946568
- Sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plc
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2013-06-01
- Primary completion
- 2015-04-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.